Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview

Alexandre Chan, Daniel L. Hertz, Manuel Morales, Elizabeth J. Adams, Sharon Gordon, Chia Jie Tan, Nathan P Staff, Jayesh Kamath, Jeong Oh, Shivani Shinde, Doreen Pon, Niharkia Dixit, James D’Olimpio, Cristina Dumitrescu, Margherita Gobbo, Kord Kober, Samantha Mayo, Linda Pang, Ishwaria Subbiah, Andreas S BeutlerKatherine B. Peters, Charles Lawrence Loprinzi, Maryam B. Lustberg

Research output: Contribution to journalReview article

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual’s specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.

Original languageEnglish (US)
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Peripheral Nervous System Diseases
Drug Therapy
Pharmaceutical Preparations
Vinca Alkaloids
Taxoids
Thalidomide
Platinum
Ion Channels
DNA Repair
Pharmacokinetics
Incidence
Genes

Keywords

  • Chemotherapy-induced peripheral neuropathy
  • CIPN
  • Neuropathy

ASJC Scopus subject areas

  • Oncology

Cite this

Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN) : MASCC neurological complications working group overview. / Chan, Alexandre; Hertz, Daniel L.; Morales, Manuel; Adams, Elizabeth J.; Gordon, Sharon; Tan, Chia Jie; Staff, Nathan P; Kamath, Jayesh; Oh, Jeong; Shinde, Shivani; Pon, Doreen; Dixit, Niharkia; D’Olimpio, James; Dumitrescu, Cristina; Gobbo, Margherita; Kober, Kord; Mayo, Samantha; Pang, Linda; Subbiah, Ishwaria; Beutler, Andreas S; Peters, Katherine B.; Loprinzi, Charles Lawrence; Lustberg, Maryam B.

In: Supportive Care in Cancer, 01.01.2019.

Research output: Contribution to journalReview article

Chan, A, Hertz, DL, Morales, M, Adams, EJ, Gordon, S, Tan, CJ, Staff, NP, Kamath, J, Oh, J, Shinde, S, Pon, D, Dixit, N, D’Olimpio, J, Dumitrescu, C, Gobbo, M, Kober, K, Mayo, S, Pang, L, Subbiah, I, Beutler, AS, Peters, KB, Loprinzi, CL & Lustberg, MB 2019, 'Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview', Supportive Care in Cancer. https://doi.org/10.1007/s00520-019-04987-8
Chan, Alexandre ; Hertz, Daniel L. ; Morales, Manuel ; Adams, Elizabeth J. ; Gordon, Sharon ; Tan, Chia Jie ; Staff, Nathan P ; Kamath, Jayesh ; Oh, Jeong ; Shinde, Shivani ; Pon, Doreen ; Dixit, Niharkia ; D’Olimpio, James ; Dumitrescu, Cristina ; Gobbo, Margherita ; Kober, Kord ; Mayo, Samantha ; Pang, Linda ; Subbiah, Ishwaria ; Beutler, Andreas S ; Peters, Katherine B. ; Loprinzi, Charles Lawrence ; Lustberg, Maryam B. / Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN) : MASCC neurological complications working group overview. In: Supportive Care in Cancer. 2019.
@article{0ab448b502834c1aa947e32a701d1b13,
title = "Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual’s specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.",
keywords = "Chemotherapy-induced peripheral neuropathy, CIPN, Neuropathy",
author = "Alexandre Chan and Hertz, {Daniel L.} and Manuel Morales and Adams, {Elizabeth J.} and Sharon Gordon and Tan, {Chia Jie} and Staff, {Nathan P} and Jayesh Kamath and Jeong Oh and Shivani Shinde and Doreen Pon and Niharkia Dixit and James D’Olimpio and Cristina Dumitrescu and Margherita Gobbo and Kord Kober and Samantha Mayo and Linda Pang and Ishwaria Subbiah and Beutler, {Andreas S} and Peters, {Katherine B.} and Loprinzi, {Charles Lawrence} and Lustberg, {Maryam B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00520-019-04987-8",
language = "English (US)",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN)

T2 - MASCC neurological complications working group overview

AU - Chan, Alexandre

AU - Hertz, Daniel L.

AU - Morales, Manuel

AU - Adams, Elizabeth J.

AU - Gordon, Sharon

AU - Tan, Chia Jie

AU - Staff, Nathan P

AU - Kamath, Jayesh

AU - Oh, Jeong

AU - Shinde, Shivani

AU - Pon, Doreen

AU - Dixit, Niharkia

AU - D’Olimpio, James

AU - Dumitrescu, Cristina

AU - Gobbo, Margherita

AU - Kober, Kord

AU - Mayo, Samantha

AU - Pang, Linda

AU - Subbiah, Ishwaria

AU - Beutler, Andreas S

AU - Peters, Katherine B.

AU - Loprinzi, Charles Lawrence

AU - Lustberg, Maryam B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual’s specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual’s specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.

KW - Chemotherapy-induced peripheral neuropathy

KW - CIPN

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=85069936053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069936053&partnerID=8YFLogxK

U2 - 10.1007/s00520-019-04987-8

DO - 10.1007/s00520-019-04987-8

M3 - Review article

C2 - 31363906

AN - SCOPUS:85069936053

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -